|
KMID : 0378019900330120119
|
|
New Medical Journal
1990 Volume.33 No. 12 p.119 ~ p.124
|
|
|
Clinical Evaluation of Cefixime(Suprax^(®)) in Urogenital Tract Infection
|
|
|
|
|
Abstract
|
|
|
Cefixime (Suprax®) is new oral third-generation cephalosporin with introduction of arninothiazole group at the seventh position. The structural change overcome many weak point of old oral cephalosporins, such as narrow spectrum, weak bacterial activity, unstable f3-lactamase and short serum half life.
We orally administrated the cefixime (Suprax®) for 3 to 14 days according to the severity and complexity of infection to 34 patients with the urogenital tract infections and evaluated the clinical response, antimicrobial susceptibility, and side effects.
The results were as follows
1. Patients distributions were simple cystitis(9 cases), complicated cystitis(8 cases), acute pyelonephritis(7 cases), urethritis(5 cases), acute epididymitis(4 cases) and prostatitis(1 case).
2. Clinical effectiveness was 91.2%. On 34 cases, 26 ´cases were excellent, 5 cases were good and 3 cases were fair.
3. Pyuria was disappeared or decreased at 88.2%.
4. On bacteriologic study, E. coli, 14 cases ; Staphylococcus epidermidis, 7 cases ; Enterococcus cloacae, 4 cases : a-hemolytic streptococcus, 2 cases ; Klebsiela oxytoca, 2 cases 7 Coalulase( -) streptococci, l case ; Klebsiela pneimonia 1 case were isolated. And 28 cases were eradicated, 2 cases were decreased in colony count, 3 cases were changed the starins, and 1 case was not changed.
5. There are two cases of side effects, mild nausea and epigastric discomfort. But, in complete blood count, blood chemistry and urine analysis, there were no remarkable change between pre and post-administration test, and considerable changes with the dosage and duration of the drug.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|